ArticleBiomedicines2025

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.

Namita A Goyal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.